혈액 분석기 및 시약 시장 보고서 : 제품 유형별, 용도별, 가격대별, 용도별, 최종사용자별, 지역별(2026-2034년)

The global hematology analyzers and reagents market size reached USD 9.9 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 16.1 Billion by 2034, exhibiting a growth rate (CAGR) of 5.42% during 2026-2034. The market is propelled by the rising incidence of blood disorders and chronic illnesses, significant technological advancements in hematology analyzers, rising geriatric population globally, significantly rising demand for point-of-care (POC) diagnostics, and integration of artificial intelligence (AI) and machine learning (ML) in the diagnostics.

Hematology analyzers and reagents play a crucial role in modern medical diagnostics, enabling the accurate and efficient assessment of blood samples. They are designed to analyze various blood parameters and provide valuable insights into a patient's health. Hematology analyzers consist of several key components, including a sample handling system, a fluidics system, a cell counting and differentiation system, and a data processing unit. Reagents used in conjunction with these analyzers help facilitate the detection and measurement of specific blood components. Hematology analyzers offer several advantages in clinical settings, such as they provide rapid results, allowing for timely diagnosis and treatment decisions. Additionally, they offer high levels of accuracy and precision, minimizing the risk of diagnostic errors. They are capable of analyzing a wide range of blood parameters, including complete blood count (CBC), white blood cell differential, and hemoglobin levels. Currently, there are different types of hematology analyzers available, ranging from compact benchtop models to larger, fully automated systems.

Hematology Analyzers and Reagents Market Trends:

The global hematology analyzers and reagents market is primarily accelerated by several key factors, including the rising prevalence of blood disorders, such as anemia, leukemia, and hemophilia. Moreover, the growing geriatric population and rapid advancements in technology, such as the integration of artificial intelligence (AI) and machine learning (ML) algorithms in hematology analyzers, are driving the market growth. Additionally, the increasing adoption of automated hematology analyzers in laboratories and hospitals, which offer rapid and precise results, is propelling the market growth. The escalating awareness about the importance of early disease detection and preventive healthcare measures and the surging demand for point-of-care testing (POCT) devices and portable hematology analyzers are other factors contributing to the market growth. In line with this, the surging expenditure in research and development (R&D) activities in hematology, focusing on the development of novel reagents and analyzers, is fueling the market growth. Furthermore, strategic collaborations and partnerships among key players to enhance their product portfolios and expand their geographical presence are favoring the market growth.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2026-2034. Our report has categorized the market based on product, usage type, price range, application, and end user.

Product Insights:

• Haematology
• Haemostasis
• Immunohaematology

Usage Type Insights:

• Standalone
• Point-of-Care

Price Range Insights:

• Low Range
• Mid-Range
• High Range

Application Insights:

• Haemorrhagic Conditions
• Infection-Related Conditions
• Immune System-Related Conditions
• Blood Cancer
• Anaemia

End User Insights:

• Commercial Service Providers
• Hospital Laboratories
• Research and Academic Institutes
• Others

Regional Insights:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for hematology analyzers and reagents. Some of the factors driving the North America hematology analyzers and reagents market included the surging demand for personalized medicine and companion diagnostics, the increasing number of clinical trials and drug development activities, and the rising demand for hematology analyzers and reagents in veterinary diagnostics.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global hematology analyzers and reagents market. Detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, Bio-Rad Laboratories Inc., Boule Diagnostics, Danaher Corporation, Diatron MI PLC (Stratec SE), EKF Diagnostics Holdings plc, Heska Corporation, Horiba Ltd., Mindray Medical International Limited, Nihon Kohden Corporation, Siemens, Sinnowa Medical Science & Technology Co. Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

• How has the global hematology analyzers and reagents market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global hematology analyzers and reagents market?
• What is the impact of each driver, restraint, and opportunity on the global hematology analyzers and reagents market?
• What are the key regional markets?
• Which countries represent the most attractive hematology analyzers and reagents market?
• What is the breakup of the market based on the product?
• Which is the most attractive product in the hematology analyzers and reagents market?
• What is the breakup of the market based on the usage type?
• Which is the most attractive usage type in the hematology analyzers and reagents market?
• What is the breakup of the market based on the price range?
• Which is the most attractive price range in the hematology analyzers and reagents market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the hematology analyzers and reagents market?
• What is the breakup of the market based on the end user?
• Which is the most attractive end user in the hematology analyzers and reagents market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global hematology analyzers and reagents market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Hematology Analyzers and Reagents Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Haematology
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Haemostasis
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Immunohaematology
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Usage Type

• 7.1 Standalone
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Point-of-Care
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Price Range

• 8.1 Low Range
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Mid-Range
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 High Range
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Application

• 9.1 Haemorrhagic Conditions
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Infection-Related Conditions
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Immune System-Related Conditions
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Blood Cancer
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Anaemia
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast

10 Market Breakup by End User

• 10.1 Commercial Service Providers
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Hospital Laboratories
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Research and Academic Institutes
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Others
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia-Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 Drivers, Restraints, and Opportunities

• 12.1 Overview
• 12.2 Drivers
• 12.3 Restraints
• 12.4 Opportunities

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Abbott Laboratories
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
  • 16.3.2 Bio-Rad Laboratories Inc.
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
  • 16.3.3 Boule Diagnostics
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
  • 16.3.4 Danaher Corporation
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
  • 16.3.5 Diatron MI PLC (Stratec SE)
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
  • 16.3.6 EKF Diagnostics Holdings plc
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
  • 16.3.7 Heska Corporation
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
  • 16.3.8 Horiba Ltd.
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
  • 16.3.9 Mindray Medical International Limited
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
  • 16.3.10 Nihon Kohden Corporation
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
  • 16.3.11 Siemens
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio
    • 16.3.11.3 Financials
  • 16.3.12 Sinnowa Medical Science & Technology Co. Ltd.
    • 16.3.12.1 Company Overview
    • 16.3.12.2 Product Portfolio